AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
After a delay, the Alpha-3 study faces an April futility analysis.
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
